Protein cages for the delivery of medical imaging and therapeutic agents

• US 20040115132A1
• Filed: 05/19/2003
• Published: 06/17/2004
• Est. Priority Date: 05/17/2002
• Status: Abandoned Application

• Current Assignee: Montana State University
• Original Assignee: Montana State University
• Inventors: Douglas, Trevor, Idzerda, Yves U., Young, Mark J.
• Application Number:
  US10/441,962
• Publication Number:
  US 20040115132A1
• Time in Patent Office: Days
• US Class Current: 424/9.34
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61K 49/189 Host-guest complexes, e.g. cyclodextrins
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.

Claims

1. A delivery agent comprising a protein cage with at least one entrapped medical imaging agent.

2. An agent according to claim 1, wherein said protein cage is a modified protein cage.

3. A agent according to claim 1 or 2, wherein said protein cage is a viral protein cage.

4. An agent according to claim 1 or 2, wherein said protein cage is a non-viral protein cage selected from the group consisting of ferritin, apoferritin, and dodecameric cages.

5. An agent according to claim 1 or 2, wherein said medical imaging agent is selected from the group comprising magnetic resonance imaging (MRI) agents, nuclear magnetic resonance imaging agents (NMR), x-ray agents, optical agents, ultrasound agents and neutron capture therapy agents.

6. An agent according to claim 5, wherein said imaging agent is an MRI agent comprising a paramagnetic metal ion.

8. An agent according to claim 6 or 7, wherein said MRI agent further comprises a chelate.

9. An agent according to claim 8, wherein said delivery agent further comprises a therapeutically active agent.

10. An agent according to claim 9, wherein said therapeutically active agent is linked to said imaging agent.

11. An agent according to claim 9, wherein said therapeutically active agent is the laminin peptide 11.

12. An agent according to claim 1, 2, or 9 wherein said delivery agent comprises a second imaging agent.

13. An agent according to claim 12, wherein said second imaging agent is different from said first medical imaging agent.

14. An agent according to claim 2, wherein said protein cage is modified such that the electrostatic environment of the interior surface of said protein cage is altered.

15. A agent according to claim 14, wherein said protein coat is modified by adding at least one glutamic acid-aspartic acid repeat.

16. An agent according to claim 2, wherein said delivery agent further comprises a targeting moiety.

17. An agent according to claim 16, wherein said targeting moiety is laminin peptide 11.

29. A method of imaging of a cell, tissue or patient comprising administering a delivery agent according to claim 1 or 2 to a cell, tissue or patient and rendering an image of said cell, tissue or patient.

30. A method according to claim 29, wherein said imaging method is selected from the group consisting of MRI, NMR, x-ray, optical ultrasound and neutron capture therapy.

31. A method of treating a disorder associated with a therapeutically active agent active comprising administering an agent according to claim 1 or 2 to a cell, tissue or patient to effect a therapeutic effect in said cell, tissue or patient.

7. An agent according to claim 7, wherein said paramagnetic metal ion is gadolinium III (Gd+3).

18. A method of making a delivery agent comprising:

a) providing an empty protein cage and at least one medical imaging agent;

b) turning on a chemical switch to allow entry of said medical imaging agent; and

,

c) turning off said chemical switch to entrap said medical imaging agent.

19. A method of making a delivery agent according to claim 18, further comprising providing at least one therapeutic agent.

20. A method of making a delivery agent according to claim 18, wherein said protein cage further comprises a targeting moiety.

21. A method of making a delivery agent according to claim 18, wherein said chemical switch is altered by the addition of cysteine residues.

22. A method of making a delivery agent according to claim 18, wherein said chemical switch is altered by the addition of histidine residues.

23. A method of making a delivery agent according to claim 18, wherein said medical imaging agent comprises an attachment linker.

24. A method according to claim 23, wherein said attachment linker is maleimide.

25. A method according to claim 23, wherein said attachment linker is a polymer.

26. A method of making a delivery agent according to claim 18, wherein said therapeutic agent comprises an attachment linker.

27. A method of making a delivery agent according to claim 26, wherein said attachment linker is a polymer.

28. An method of making a delivery agent according to claim 26 wherein said attachment linker is maleimide.